EUVIMEDEUVIMED entdecken
Crossref

Nanocarriers for Peptide-Based Therapeutics Against Sexually Transmitted Vaginal Infections

Zahra Sheikh Soleimany Darany, Maryam Mohammadi, Neda Arjmand, Satinik Darzi, Fateme Haghi Koumle, Shiva Khodarahmi

Nanomedicine Research Journal · 2026-03 · 11 (1) · 19-26

DOI: 10.22034/nmrj.2026.01.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nanomedicine Research Journal, 2026-03. Verfasst von Zahra Sheikh Soleimany Darany und 5 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nanocarrier-based peptide therapeutics offer a promising strategy to combat sexually transmitted vaginal infections, including bacterial vaginosis, vulvovaginal candidiasis, trichomoniasis, and other STIs that are often recurrent and inadequately managed by conventional therapies. Antimicrobial and immunomodulatory peptides provide broad-spectrum activity against bacterial, fungal, and viral pathogens but are limited by poor stability, enzymatic degradation, low bioavailability, and potential toxicity in the vaginal environment. Encapsulation in nanocarriers such as liposomes, polymeric nanoparticles, nanogels, micelles, and dendrimers can protect peptides, enhance mucoadhesion or mucus penetration, prolong residence time, and enable controlled or stimuli-responsive release at the site of infection.This review summarizes the pathophysiology of sexually transmitted vaginal infections and the roles of key pathogens, biofilms, mucus barriers, and antimicrobial resistance in limiting current treatments. It discusses the mechanisms, advantages, and limitations of antimicrobial peptides, with emphasis on formulation and design strategies to enhance their stability, selectivity, and safety for intravaginal use. Recent advances in vaginally targeted nanocarrier platforms and preclinical in vitro, ex vivo, and in vivo evidence demonstrating improved efficacy, tissue coverage, retention, and biocompatibility of peptide-loaded systems are highlighted. Remaining challenges in large-scale manufacturing, long-term safety, and regulatory approval, as well as future opportunities for smart and potentially personalized nanocarrier–peptide systems, are outlined to guide translation toward clinical application.

Schlagwörter

vaginal infectionsantimicrobial peptidespeptide therapeuticsnanocarriersdrug delivery

Zitieren

APA

Darany, Z. S. S., Mohammadi, M., Arjmand, N., Darzi, S., Koumle, F. H., & Khodarahmi, S. (2026). Nanocarriers for Peptide-Based Therapeutics Against Sexually Transmitted Vaginal Infections. Nanomedicine Research Journal, 11(1), 19-26. https://doi.org/10.22034/nmrj.2026.01.003

Vancouver

Darany ZSS, Mohammadi M, Arjmand N, Darzi S, Koumle FH, Khodarahmi S. Nanocarriers for Peptide-Based Therapeutics Against Sexually Transmitted Vaginal Infections. Nanomedicine Research Journal. 2026;11(1):19-26. doi:10.22034/nmrj.2026.01.003

BibTeX
@article{Darany2026,
  author = {Darany, Zahra Sheikh Soleimany and Mohammadi, Maryam and Arjmand, Neda and Darzi, Satinik and Koumle, Fateme Haghi and Khodarahmi, Shiva},
  title = {Nanocarriers for Peptide-Based Therapeutics Against Sexually Transmitted Vaginal Infections},
  journal = {Nanomedicine Research Journal},
  year = {2026},
  volume = {11},
  number = {1},
  pages = {19--26},
  doi = {10.22034/nmrj.2026.01.003}
}
Kostenlos starten →